1. PRODUCT NAME
SYMBICORT® 100/6 TURBUHALER®, inhalation powder
SYMBICORT® 200/6 TURBUHALER®, inhalation powder
SYMBICORT® 400/12 TURBUHALER®, inhalation powder

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SYMBICORT 100/6 TURBUHALER
SYMBICORT 100/6 TURBUHALER delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler monoproducts, i.e. budesonide 100 micrograms/inhalation (metered dose) and formoterol fumarate dihydrate 6 micrograms/inhalation (metered dose).

Each delivered dose (the dose that leaves the mouthpiece) contains as active constituents: budesonide 80 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation.

Each inhaler contains 60 doses or 120 doses

SYMBICORT 200/6 TURBUHALER
SYMBICORT 200/6 TURBUHALER delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler monoproducts, i.e. budesonide 200 micrograms/inhalation (metered dose) and formoterol fumarate dihydrate 6 micrograms/inhalation (metered dose).

Each delivered dose (the dose that leaves the mouthpiece) contains as active constituents: budesonide 160 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation.

Each inhaler contains 60 doses or 120 doses

SYMBICORT 400/12 TURBUHALER
SYMBICORT 400/12 TURBUHALER delivers the same amount of budesonide and formoterol as the corresponding Turbuhaler monoproducts, i.e. budesonide 400 micrograms/inhalation (metered dose) and formoterol fumarate dihydrate 12 micrograms/inhalation (metered dose).

Each delivered dose (the dose that leaves the mouthpiece) contains as active constituents: budesonide 320 micrograms/inhalation and formoterol fumarate dihydrate 9 micrograms/inhalation.

Each inhaler contains 60 doses

Formoterol fumarate dihydrate is hereafter referred to as formoterol.
3. PHARMACEUTICAL FORM

Inhalation powder

4. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Asthma
SYMBICORT TURBUHALER is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations.

SYMBICORT TURBUHALER is suitable for any asthma severity, where the use of inhaled corticosteroids is appropriate (See Section 4.2 Dose and Method of Administration).

COPD
SYMBICORT TURBUHALER is indicated in the regular treatment of adult patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [FEV1 ≤50% of predicted normal], with frequent symptoms despite beta-2-agonist use and a history of exacerbations.

SYMBICORT should not be used for the initiation of bronchodilator therapy in COPD.

4.2 DOSE AND METHOD OF ADMINISTRATION

The dosage of SYMBICORT TURBUHALER should be individualised according to disease severity.

ASTHMA

SYMBICORT can be used according to different treatment approaches:

A. SYMBICORT anti-inflammatory reliever therapy (patients with mild disease).
B. SYMBICORT anti-inflammatory reliever plus maintenance therapy

As an alternative, SYMBICORT TURBUHALER can be used in a fixed dose therapy:

C. SYMBICORT maintenance therapy (fixed dose)

If patients take SYMBICORT as a maintenance therapy, they should be instructed to take the maintenance dose of SYMBICORT TURBUHALER even when asymptomatic for optimal benefit.

A. SYMBICORT anti-inflammatory reliever therapy (patients with mild disease):
SYMBICORT TURBUHALER 200/6 is taken as needed for the relief of asthma symptoms when they occur, and to prevent allergen induced bronchoconstriction or exercise induced bronchoconstriction (or to prevent symptoms in those circumstances recognised by the patient to precipitate an asthma attack). The formoterol component in SYMBICORT TURBUHALER provides fast onset of effect (within 1-3 minutes) with long-acting (at least 12 hours after a
single dose) bronchodilation in reversible airways obstruction. Patients should be advised to always have SYMBICORT TURBUHALER 200/6 available for relief of symptoms.

Clinical studies have demonstrated that SYMBICORT TURBUHALER 200/6 anti-inflammatory reliever therapy provides significant reductions in severe exacerbations and was statistically superior on daily asthma symptom control compared to a short-acting beta-2 agonist therapy alone (see section 5.1 Pharmacodynamic properties).

**Recommended doses:**
Physicians should discuss allergen exposure and exercise patterns with the patients and take these into consideration when recommending the dose frequency.

**Adults and adolescents (12 years and older):** Patients should take 1 inhalation of SYMBICORT TURBUHALER 200/6 as needed in response to symptoms and for the prevention of allergen induced bronchoconstriction or exercise induced bronchoconstriction to control asthma. If symptoms persist after a few minutes, 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.

A total daily dose of more than 8 inhalations is normally not needed, however a total daily dose of up to 12 inhalations can be used temporarily. Patients using more than 8 inhalations daily should be reassessed for alternative explanations of persisting symptoms.

**Children (4 years and older):** Efficacy and safety of SYMBICORT anti-inflammatory reliever therapy in children 4-11 years have not been studied.

**B. SYMBICORT anti-inflammatory reliever plus maintenance therapy**
When maintenance treatment with a combination of inhaled corticosteroid and long-acting beta-2-agonist (LABA) is required, SYMBICORT is taken as anti-inflammatory reliever therapy and in addition, patients take a daily maintenance dose of SYMBICORT TURBUHALER. The as-needed inhalations provide both rapid relief of symptoms and improved overall asthma control. Patients should be advised to have SYMBICORT TURBUHALER available for relief of symptoms at all times. A separate inhaler for relief of symptoms is not necessary.

Clinical studies have demonstrated that SYMBICORT anti-inflammatory reliever plus maintenance therapy provides clinically meaningful reductions in severe exacerbations while maintaining symptom control, compared to SYMBICORT maintenance therapy with a separate short-acting bronchodilator (see section 5.1 Pharmacodynamic properties).

The maintenance dose should be titrated to the lowest dose at which effective control of asthma is maintained.

**Recommended doses:**
Physicians should discuss allergen exposure and exercise patterns with the patients and take these into consideration when recommending the dose frequency.

**Adults and adolescents (12 years and older):**
Patients should take 1 inhalation of SYMBICORT TURBUHALER 100/6 or 200/6 as needed in response to symptoms to control asthma. Patients on SYMBICORT TURBUHALER 200/6 can also take 1 inhalation for the prevention of allergen induced bronchoconstriction or EIB. If symptoms persist after a few minutes, 1 additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
Patients also take the recommended maintenance dose, which is 2 inhalations of SYMBICORT TURBUHALER 100/6 or 200/6 per day, given either as 1 inhalation in the morning and one in the evening or as 2 inhalations in either the morning or the evening. For some patients, a maintenance dose of 2 inhalations twice daily may be appropriate.

A total daily dose of more than 8 inhalations is not normally needed, however a total daily dose of up to 12 inhalations can be used temporarily. If the patient experiences deteriorating symptoms after taking the appropriate maintenance therapy and additional as needed inhalations, the patient should be reassessed for alternative explanations of persisting symptoms.

**Note** - SYMBICORT TURBUHALER 400/12 should not be used for the SYMBICORT anti-inflammatory reliever plus maintenance therapy regimen.

**Children (4 years and older):**
Patients should take 1 inhalation of SYMBICORT TURBUHALER 100/6 as needed in response to symptoms to control asthma. If symptoms persist after a few minutes, an additional inhalation should be taken.

Not more than 4 inhalations should be taken on any single occasion.

Patients also take the recommended maintenance dose, which is 1 inhalation of SYMBICORT TURBUHALER 100/6 once daily.

A total daily dose of more than 4 inhalations is not normally needed, however a total daily dose of up to 8 inhalations could be used temporarily.

A reassessment of asthma therapy should be considered in patients using an increasing number of SYMBICORT inhalations for symptom relief without achieving improved asthma control within 2 weeks.

**C. SYMBICORT maintenance therapy (fixed dose):**
When maintenance treatment with a combination of inhaled corticosteroid and long-acting beta-2-agonist is required, SYMBICORT is taken as a fixed daily dose treatment, with a separate short-acting bronchodilator for relief of symptoms. Patients should be advised to have their separate short-acting bronchodilator available for relief of symptoms at all times.

Increasing use of a separate short-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy.

When control has been achieved, the dose should be titrated to the lowest dose at which effective control of symptoms is maintained.

**Adults and adolescents (12 years and older):**

<table>
<thead>
<tr>
<th>SYMBICORT 100/6:</th>
<th>1-2 inhalations once or twice daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum daily maintenance dose: 4 inhalations (2 inhalations twice daily).</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMBICORT 200/6:</th>
<th>1-2 inhalations once or twice daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum daily maintenance dose: 4 inhalations. (2 inhalations twice daily).</td>
<td></td>
</tr>
</tbody>
</table>
During worsening of asthma the dose of SYMBICORT 100/6 and 200/6 may temporarily be increased to a maximum of 4 inhalations twice daily in adults.

SYMBICORT 400/12: 1 inhalation once or twice daily
Maximum daily maintenance dose: 2 inhalations (1 inhalation twice daily).

During worsening of asthma the dose of SYMBICORT 400/12 may temporarily be increased to a maximum of 2 inhalations twice daily in adults.

Children (4 years and older):
SYMBICORT 100/6: 1-2 inhalations twice daily.
Maximum daily maintenance dose: 4 inhalations.

SYMBICORT 200/6: 1 inhalation twice daily.
Maximum daily maintenance dose: 2 inhalations.

SYMBICORT 400/12: Efficacy and safety have not been fully studied in children for SYMBICORT 400/12.

Children under 4 years of age:
The use of SYMBICORT TURBUHALER is not recommended in children under four years of age.

COPD

Adults (40 years and older):
SYMBICORT 200/6: 2 inhalations twice daily
Maximum daily maintenance dose: 4 inhalations

SYMBICORT 400/12: 1 inhalation twice daily
Maximum daily maintenance dose: 2 inhalations.

SPECIAL POPULATIONS
There is no special dosing requirement in elderly patients.

There are no data available for use of SYMBICORT TURBUHALER in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver disease.

INSTRUCTIONS FOR CORRECT USE OF SYMBICORT TURBUHALER
SYMBICORT TURBUHALER is inspiratory flow-driven which means that, when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.

Note: It is important to instruct the patient to:
● carefully read the instructions for use in the patient information leaflet which are packed together with each inhaler
● breath in forcefully and deeply through the mouthpiece to ensure that an optimal dose is delivered to the lungs
● never to breathe out through the mouthpiece
● replace the cover of the SYMBICORT TURBUHALER after use
● rinse the mouth out with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush

The patient may not taste or feel any medication when using SYMBICORT TURBUHALER due to the small amount of medicine dispensed.

4.3 CONTRAINDICATIONS
Hypersensitivity to budesonide, formoterol or to lactose.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
For treatment of severe exacerbations, a combination product of inhaled corticosteroid and long-acting beta-2-agonist alone is not sufficient.

Dosing and discontinuation
The management of asthma should normally follow a stepwise programme, and patient response should be monitored clinically and by lung function tests.

The lowest effective dose of SYMBICORT TURBUHALER should be used.

Patients should be reminded to take their SYMBICORT TURBUHALER maintenance dose as prescribed, even when asymptomatic. They should also be advised to have their rescue inhaler available at all times, either SYMBICORT TURBUHALER (for asthma patients on anti-inflammatory reliever therapy) or a separate short-acting bronchodilator (for asthma patients using SYMBICORT TURBUHALER as maintenance therapy only and for COPD patients).

In patients using SYMBICORT TURBUHALER as an anti-inflammatory reliever (asthma therapies A and B), the reliever inhalations of SYMBICORT TURBUHALER should be taken in response to asthma symptoms and for the prevention of allergen- or exercise-induced bronchoconstriction to control asthma.

If the patient finds the treatment ineffective or exceeds the prescribed dose of SYMBICORT TURBUHALER, the patient should be reviewed by a physician.

Once asthma symptoms are controlled, consideration may be given to stepping down treatment with SYMBICORT TURBUHALER. Regular review of patients as treatment is stepped down is important.

It is recommended that the maintenance dose is tapered when long-term treatment with SYMBICORT TURBUHALER is to be discontinued and the dosing should not be stopped abruptly. Complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm the diagnosis of asthma.

Deterioration of asthma control
Increasing use of SYMBICORT TURBUHALER for reliever therapy or short-acting bronchodilators to relieve symptoms indicates deterioration of control.
Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present. Patients should be advised to seek medical attention if they find the treatment ineffective or they have exceeded the prescribed dose of SYMBICORT TURBUHALER.

**Asthma exacerbations**

Serious asthma-related adverse events and exacerbations may occur during treatment with SYMBICORT TURBUHALER. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen during treatment with SYMBICORT TURBUHALER.

Patients should be advised to seek medical attention if they experience deteriorating symptoms after taking the appropriate maintenance therapy and additional as needed inhalations if using SYMBICORT TURBUHALER as an anti-inflammatory reliever.

**Potential systemic effects of inhaled corticosteroids**

SYMBICORT TURBUHALER contains an inhaled corticosteroid (budesonide).

SYMBICORT TURBUHALER should not be used to initiate treatment with inhaled corticosteroids in patients being transferred from oral steroids.

Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. However, these effects are much less likely to occur with inhalation treatment than with oral corticosteroids. Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, and glaucoma and more rarely a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important, therefore, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.

Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur.

Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity. Therefore it is important that the patient is reviewed regularly and the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.

**HPA axis suppression and adrenal insufficiency**

Dose-dependent HPA axis suppression (as indicated by 24 hour urinary and/or plasma cortisol AUC) has been observed with inhaled budesonide, although the physiological circadian rhythms of plasma cortisol were preserved. This indicates that the HPA axis suppression represents a physiological adaptation in response to inhaled budesonide, not necessarily adrenal insufficiency. The lowest dose that results in clinically relevant adrenal insufficiency has not been established. Very rare cases of clinically relevant adrenal dysfunction have been reported in patients using inhaled budesonide at recommended doses.
Clinically important disturbances of the HPA axis and/or adrenal insufficiency induced by severe stress (eg trauma, surgery, infection in particular gastroenteritis or other conditions associated with severe electrolyte loss) may be related to inhaled budesonide in specific patient populations. These are patients with prolonged treatment at the highest recommended dose of SYMBICORT and patients administered concomitant CYP3A4-inhibitors (see section 4.5). Monitoring for signs of adrenal dysfunction is advisable in these patient groups. For these patients additional systemic glucocorticosteroid cover should be considered during periods of stress, a severe asthma attack or elective surgery.

**Transfer from oral therapy**

Particular care is needed in patients transferring from oral steroids, since they may remain at risk of impaired adrenal function for a considerable time. Patients who have required high-dose emergency corticosteroid therapy or prolonged treatment at a higher recommended dose of inhaled corticosteroids may also be at risk. These patients may exhibit signs and symptoms of adrenal insufficiency when exposed to severe stress. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

Care should be taken when commencing SYMBICORT TURBUHALER treatment, particularly if there is any reason to suspect that adrenal function is impaired from previous systemic steroid therapy.

**Bone density**

Whilst corticosteroids may have an effect on bone mass at high doses, studies with budesonide treatment in adults at recommended doses, have not demonstrated any significant effect on bone mineral density. No information regarding the effect of Symbicort Turbuhaler at higher doses is available.

Bone mineral density measurements in children should be interpreted with caution as an increase in bone area in growing children may reflect an increase in bone volume. In three large medium to long term (12 months - 6 years) studies in children (5-16 years), no effects on bone mineral density were observed after treatment with budesonide (189 - 1322μg/day) compared to nedocromil, placebo or age matched controls. However, in a randomised 18 month study (n=176; 5-10 years), bone mineral density was significantly decreased by 0.11 g/cm² (p=0.023) in the group treated with inhaled budesonide via Turbuhaler compared with the group treated with inhaled disodium cromoglycate. The dose of budesonide was 400 micrograms bd for 1 month, 200 micrograms bd for 5 months and 100 micrograms bd for 12 months and the dose of disodium cromoglycate 10 milligram tid. The clinical significance of this result remains uncertain.

**Growth in children**

Long term studies suggest that children and adolescents treated with inhaled budesonide ultimately achieve their adult target height. However an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment.

It is recommended that the height of children and adolescents receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible.

Physicians should carefully weigh the benefits of the corticosteroid therapy against the possible risk of growth suppression.
Oropharyngeal Candida Infection
Candida infection in the oropharynx has been reported due to drug deposition in association with inhalation therapy. To minimise the risk of oropharyngeal candida infection (see section 4.8 Undesirable Effects), the patient should be instructed to rinse their mouth out with water after inhaling the maintenance dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations. Oropharyngeal candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroids.

Paradoxical bronchospasm
As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath after dosing. If the patient experiences paradoxical bronchospasm SYMBICORT TURBUHALER should be discontinued immediately, the patient should be assessed, and an alternative therapy instituted if necessary. Paradoxical bronchospasm responds to a short-acting inhaled bronchodilator and should be treated straightaway.

Patients with other medical conditions

Infections / Tuberculosis
Signs of existing infection may be masked by the use of high doses of glucocorticosteroids and new infections may appear during their use.

As with all inhaled medication containing corticosteroids, SYMBICORT TURBUHALER should be administered with caution in patients with active or quiescent pulmonary tuberculosis or fungal, bacterial or viral infections of the respiratory system.

Sensitivity to sympathomimetic amines
In patients with increased susceptibility to sympathomimetic amines (e.g. inadequately controlled hyperthyroidism), formoterol should be used with caution.

Thyrotoxicosis
SYMBICORT TURBUHALER should be administered with caution in patients with thyrotoxicosis.

Cardiovascular disorders
Beta-2-agonists have an arrhythmogenic potential that must be considered before commencing treatment for bronchospasm. Cardiovascular effects, such as increases in systolic blood pressure and heart rate, may occasionally be seen with all sympathomimetic medicines, especially at higher than therapeutic doses.

The effects of formoterol in acute as well as chronic toxicity studies were seen mainly on the cardiovascular system and consisted of hyperaemia, tachycardia, arrhythmias and myocardial lesions. These are known pharmacological manifestations seen after administration of high doses of beta-2-adrenoceptor agonists.

Patients with pre-existing cardiovascular conditions may be at greater risk of developing adverse cardiovascular effects following administration of beta-2 adrenoreceptor agonists. Caution is advised when formoterol is administered to patients with severe cardiovascular disorders such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
QTc-interval prolongation
Caution should be observed when treating patients with prolongation of the QTc-interval. Formoterol itself may induce prolongation of the QTc-interval.

Hypokalaemia
SYMBICORT TURBUHALER should be administered with caution in patients predisposed to low levels of serum potassium.

High doses of beta-2 agonists can lower serum potassium by inducing a redistribution of potassium from the extracellular to the intracellular compartment, via stimulation of Na⁺/K⁺-ATPase in muscle cells.

Concomitant treatment of beta-2 adrenoceptor agonists with drugs which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the beta-2 adrenoceptor agonist. Potentially serious hypokalaemia may result.

Particular caution is advised in unstable or acute severe asthma as the associated risk may be augmented by hypoxia. The hypokalaemic effect may be potentiated by concomitant treatments (see section 4.5). Patients receiving digoxin are particularly sensitive to hypokalaemia. Serum potassium levels should therefore be monitored in such situations.

Diabetes mellitus
SYMBICORT TURBUHALER should be administered with caution in patients with diabetes mellitus.

Due to the blood-glucose increasing effects of beta-2-stimulants extra blood glucose controls are initially recommended when diabetic patients are commenced on formoterol.

Lactose Intolerance
SYMBICORT TURBUHALER contains lactose (<1 mg/inhalation). This amount does not normally cause problems in lactose intolerant people. The excipient lactose contains small amounts of milk proteins which may cause allergic reactions.

Pneumonia in COPD patients
Clinical studies and meta-analyses indicate that maintenance treatment of COPD with inhaled corticosteroids may lead to an increased risk of pneumonia.

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap.

Drug interaction potential
Concomitant treatment with ritonavir, itraconazole, ketoconazole or other potent CYP3A4 inhibitors should be avoided (see section 4.5). If this is not possible, the time interval between administration of the interacting drugs should be as long as possible.

In patients using potent CYP3A4 inhibitors, SYMBICORT as an anti-inflammatory reliever is not recommended.

In vivo studies have shown that oral administration of ketoconazole or itraconazole (known inhibitors of CYP3A activity in the liver and in the internal mucosa, also see section 4.5) may
cause an increase in the systemic exposure to budesonide, and consequently lead to systemic adverse reactions, such as Cushing’s Syndrome. This is of limited importance for short-term (1-2 weeks) treatment, but should be taken into consideration during long-term treatment.

4.5 INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION

Budesonide and formoterol have not been observed to interact with any other medicines used in the treatment of asthma.

Formoterol

Beta-receptor blocking agents:
Beta-receptor blocking agents (including eye drops), especially those that are non-selective, may partially or totally inhibit the effect of beta-2-agonists, such as formoterol. These medicines may also increase airway resistance, therefore the use of these medicines in asthma patients is not recommended.

Other sympathomimetic agents:
Other beta-adrenergic stimulants or sympathomimetic amines such as ephedrine should not be given concomitantly with formoterol, since the effects will be cumulative. Patients who have already received large doses of sympathomimetic amines should not be given formoterol.

Xanthine derivatives, mineralocorticosteroids and diuretics:
Hypokalaemia may result from beta-2-agonist therapy and may be potentiated by concomitant treatment with xanthine derivatives, mineralocorticosteroids, and diuretics, such as thiazides and loop diuretics (see section 4.4).

Monoamine oxidase inhibitors, tricyclic antidepressants, quinidine, disopyramide, procainamide, phenothiazines and antihistamines:
The adverse cardiovascular effects of formoterol may be exacerbated by concurrent administration of medicines associated with QT interval prolongation. For this reason caution is advised when formoterol is administered to patients already taking monoamine oxidase inhibitors, tricyclic antidepressants, quinidine, disopyramide, procainamide, phenothiazines or antihistamines associated with QT interval prolongation (e.g. terfenadine, astemizole) as these can prolong the QTc-interval and increase the risk of cardiovascular effects such as ventricular arrhythmias.

L-Dopa, L-thyroxine, oxytocin and alcohol:
L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards beta-2 sympathomimetics.

Budesonide

CYP3A4 Inhibitors
The metabolism of budesonide is primarily mediated by CYP3A4. Potent CYP3A4 inhibitors may therefore increase plasma levels and thus systemic exposure to budesonide. This is of limited clinical importance for short-term (1-2 weeks) treatment with potent CYP3A4 inhibitors but should be taken into consideration during long-term treatment. If a patient requires long-term concomitant treatment with Symbicort and a potent CYP3A4 inhibitor, the benefit should be weighed against the increased risk of systemic corticosteroid side effects, patients should
be monitored for corticosteroid side effects and/or a reduction of the inhaled corticosteroid dose could be considered.

In patients using potent CYP3A4 inhibitors, SYMBOICORT as an anti-inflammatory reliever is not recommended.

At recommended doses, cimetidine has a slight but clinically insignificant effect and omeprazole has no effect on the pharmacokinetics of oral budesonide.

4.6 FERTILITY, PREGNANCY AND LACTATION

Pregnancy

SYMBOICORT TURBUHALER should only be used in pregnancy if the potential benefits outweigh the potential risks to the foetus. Only after special consideration should SYMBOICORT TURBUHALER be used during the first 3 months and shortly before delivery.

SYMBOICORT TURBUHALER should be used during labour only if the potential benefit justifies the potential risk.

For SYMBOICORT TURBUHALER or the concomitant treatment with budesonide and formoterol, no clinical data on exposed pregnancies are available. Data from an embryo-foetal development study in the rat, showed no evidence of any additional effect from the combination.

There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see section 5.3).

Data in more than 17000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide.

Breast-feeding

Administration of SYMBOICORT TURBUHALER to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.

Budesonide is excreted in breast milk; however, due to the relatively low doses used via the inhaled route, the amount of drug present in the breast milk, if any, is likely to be low. Consequently, no adverse effects due to budesonide are anticipated in breast-fed children whose mothers are receiving therapeutic doses of SYMBOICORT.

It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

SYMBOICORT TURBUHALER is not expected to adversely affect the ability to drive or use machines.
4.8 UNDESIRABLE EFFECTS

Since SYMBICORT TURBUHALER contains both budesonide and formoterol, the same pattern of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug-related adverse reactions are pharmacologically predictable side-effects of beta-2-agonist therapy, such as tremor and palpitations. These tend to be mild and disappear within a few days of treatment.

Adverse events which have been associated with budesonide and/or formoterol are given below listed by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10000 to < 1/1000) and very rare (< 1/10 000).

Table 1 - Adverse Drug Reactions by frequency and system organ class (SOC)

<table>
<thead>
<tr>
<th>Frequency</th>
<th>SOC</th>
<th>Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td><strong>Cardiac disorders:</strong></td>
<td>Palpitations</td>
</tr>
<tr>
<td></td>
<td><strong>Infections and infestations:</strong></td>
<td>Candida infections in oropharynx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pneumonia (in COPD patients)</td>
</tr>
<tr>
<td></td>
<td><strong>Nervous system disorders:</strong></td>
<td>Headache, tremor</td>
</tr>
<tr>
<td></td>
<td><strong>Respiratory, thoracic and mediastinal disorders:</strong></td>
<td>Mild irritation in the throat, coughing, hoarseness</td>
</tr>
<tr>
<td>Uncommon</td>
<td><strong>Cardiac disorders:</strong></td>
<td>Tachycardia</td>
</tr>
<tr>
<td></td>
<td><strong>Gastrointestinal disorders:</strong></td>
<td>Nausea, diarrhoea</td>
</tr>
<tr>
<td></td>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td>Weight gain</td>
</tr>
<tr>
<td></td>
<td><strong>Musculoskeletal and connective tissue disorders:</strong></td>
<td>Muscle cramps</td>
</tr>
<tr>
<td></td>
<td><strong>Nervous system disorders:</strong></td>
<td>Dizziness, taste disturbances, thirst, tiredness</td>
</tr>
<tr>
<td></td>
<td><strong>Psychiatric disorders:</strong></td>
<td>Agitation, restlessness, nervousness, sleep disturbances</td>
</tr>
<tr>
<td>Rare</td>
<td><strong>Cardiac disorders:</strong></td>
<td>Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles</td>
</tr>
<tr>
<td></td>
<td><strong>Immune system disorders:</strong></td>
<td>Immediate and delayed hypersensitivity reactions, e.g. dermatitis, exanthema, urticaria, pruritus, angioedema and</td>
</tr>
<tr>
<td>Frequency</td>
<td>SOC</td>
<td>Reaction</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Respiratory, thoracic and mediastinal</td>
<td>anaphylactic reaction</td>
</tr>
<tr>
<td></td>
<td>disorders:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skin and subcutaneous tissue disorders:</td>
<td>Bronchospasm</td>
</tr>
<tr>
<td></td>
<td>Metabolism and nutrition disorders</td>
<td>Skin bruising</td>
</tr>
<tr>
<td>Very rare</td>
<td>Cardiac disorders:</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolongation of the QTc-interval</td>
</tr>
<tr>
<td></td>
<td>Endocrine disorders:</td>
<td>Signs or symptoms of systemic glucocorticosteroid effects, e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density</td>
</tr>
<tr>
<td></td>
<td>Eye disorders:</td>
<td>Cataract</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Glaucoma</td>
</tr>
<tr>
<td></td>
<td>Metabolism and nutrition disorders:</td>
<td>Hyperglycaemia</td>
</tr>
<tr>
<td></td>
<td>Psychiatric disorders:</td>
<td>Anxiety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Depression, Behavioural disturbances</td>
</tr>
<tr>
<td></td>
<td>Vascular disorders:</td>
<td>Variations in blood pressure</td>
</tr>
</tbody>
</table>

Treatment with beta-2 adrenoceptor agonists may also result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).
4.9 OVERDOSE

Formoterol
An overdose of formoterol would likely lead to effects that are typical for beta-2-adrenergic agonists: tremor, headache, palpitations, and tachycardia. Hypotension, metabolic acidosis, prolonged QTc-interval, arrhythmia, nausea, vomiting, hypokalaemia and hyperglycaemia may also occur.

Supportive and symptomatic treatment may be indicated. Beta-blockers should be used with care because of the possibility of inducing bronchospasm in sensitive individuals.

If SYMBICORT TURBUHALER therapy has to be withdrawn due to overdose of the formoterol component, provision of appropriate inhaled corticosteroid therapy must be considered.

Budesonide
Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects may appear, such as hypercorticism and adrenal suppression.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764 766).

5. PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Adrenergics and other drugs for obstructive airway diseases.
ATC code: R03AK07

Mechanisms of action and pharmacodynamic effects
SYMBICORT contains budesonide and formoterol, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used both as reliever therapy, and as maintenance therapy.

Budesonide
Budesonide is a glucocorticosteroid which when inhaled has a rapid (within hours) and dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.

Formoterol
Formoterol is a selective beta-2-adrenergic agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose dependent, with an onset of effect within 1-3 minutes after inhalation. The duration of effect is at least 12 hours after a single dose.
CLINICAL EFFICACY AND SAFETY

Symbicort Turbuhaler

Clinical Efficacy for Symbicort as an anti-inflammatory reliever: anti-inflammatory reliever therapy (therapy A) and anti-inflammatory reliever plus maintenance therapy (therapy B) in asthma (see section 4.2 Dose and Method of Administration).

Overall, 20,140 asthma patients were included in 7 double-blind clinical studies, of which 7,831 were randomised to a therapy which included Symbicort as an anti-inflammatory reliever, both with a maintenance (therapy B) and without a maintenance dosing (therapy A).

A total of 8,064 asthma patients with mild asthma were included in 2 double-blind efficacy and safety studies (SYGMA 1 and SYGMA 2 studies), of which 3,384 patients were randomised to Symbicort anti-inflammatory reliever therapy (therapy A) for 12 months. Patients were required to be uncontrolled on only short-acting inhaled bronchodilator as needed or controlled on a low dose of inhaled corticosteroids or leukotriene receptor agonist plus short-acting inhaled bronchodilator as needed.

In the SYGMA 2 study, Symbicort 200/6 used as needed in response to symptoms (anti-inflammatory reliever therapy – therapy A) was comparable to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with as-needed short-acting beta-2-agonist in terms of the rate of severe exacerbations (Table 2). Protection against severe exacerbation was achieved with a 75% reduction in median inhaled steroid load. The SYGMA 1 study showed that Symbicort anti-inflammatory reliever therapy provided statistically significant and clinically meaningful reduction in the rate of annual severe exacerbation by 64% compared with as-needed use of a short-acting beta-2-agonist (Table 2). Reduction in the annual rate of moderate to severe exacerbations was consistent (60%) with that observed for severe exacerbations ([RR] 0.40, 95% CI 0.32 to 0.49, p-value <0.001).

In the SYGMA 1 study, as-needed use of Symbicort 200/6 provided superior daily asthma symptom control compared to as-needed short-acting beta-2-agonist (OR 1.14, 95% CI 1.00 to 1.30, p-value 0.046), showing a mean percentage of weeks with well-controlled asthma of 34.4% and 31.1%, respectively. Asthma symptom control was inferior for Symbicort as needed compared to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with as-needed short-acting beta-2-agonist (OR 0.64, 2-sided 95% CI 0.57 to 0.73, lower limit of the CI ≥ 0.8 for non-inferiority), showing a mean percentage of well-controlled asthma weeks of 34.4% and 44.4%, respectively. Improvements in asthma control (as defined by ACQ5) in patients using Symbicort anti-inflammatory reliever therapy were superior to improvements in patients using a short-acting beta-2-agonist as needed (-0.15, 95% CI -0.20 to -0.11, p-value < 0.001). Improvements in asthma control were lower for Symbicort as needed compared to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with a short-acting beta-2-agonist to be used as needed (SYGMA 1: 0.15, 95% CI 0.10 to 0.20; SYGMA 2: 0.11, 95% CI 0.07 to 0.15, both p-value < 0.001). For both comparisons, mean differences in treatments’ effect upon ACQ5 are not clinically meaningful (as assessed by a difference of greater than or equal to 0.5). These results were observed in a clinical study setting with considerably higher adherence to budesonide maintenance dosing than expected in real life.

In the SYGMA studies, increases in lung function compared to baseline (mean pre-bronchodilator FEV1) were statistically significantly larger for patients on Symbicort anti-inflammatory reliever therapy compared to patients on as-needed short-acting beta-2-agonist treatment. Statistically significantly smaller increases were observed for Symbicort as needed compared to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with a short-acting beta-2-agonist for 12 months. Protection against severe exacerbation was achieved with a 75% reduction in median inhaled steroid load. Reduction in the annual rate of moderate to severe exacerbations was consistent (60%) with that observed for severe exacerbations ([RR] 0.40, 95% CI 0.32 to 0.49, p-value <0.001).

In the SYGMA 2 study, Symbicort 200/6 used as needed in response to symptoms (anti-inflammatory reliever therapy – therapy A) was comparable to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with as-needed short-acting beta-2-agonist in terms of the rate of severe exacerbations (Table 2). Protection against severe exacerbation was achieved with a 75% reduction in median inhaled steroid load. The SYGMA 1 study showed that Symbicort anti-inflammatory reliever therapy provided statistically significant and clinically meaningful reduction in the rate of annual severe exacerbation by 64% compared with as-needed use of a short-acting beta-2-agonist (Table 2). Reduction in the annual rate of moderate to severe exacerbations was consistent (60%) with that observed for severe exacerbations ([RR] 0.40, 95% CI 0.32 to 0.49, p-value <0.001). In the SYGMA 1 study, as-needed use of Symbicort 200/6 provided superior daily asthma symptom control compared to as-needed short-acting beta-2-agonist (OR 1.14, 95% CI 1.00 to 1.30, p-value 0.046), showing a mean percentage of weeks with well-controlled asthma of 34.4% and 31.1%, respectively. Asthma symptom control was inferior for Symbicort as needed compared to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with as-needed short-acting beta-2-agonist (OR 0.64, 2-sided 95% CI 0.57 to 0.73, lower limit of the CI ≥ 0.8 for non-inferiority), showing a mean percentage of well-controlled asthma weeks of 34.4% and 44.4%, respectively. Improvements in asthma control (as defined by ACQ5) in patients using Symbicort anti-inflammatory reliever therapy were superior to improvements in patients using a short-acting beta-2-agonist as needed (-0.15, 95% CI -0.20 to -0.11, p-value < 0.001). Improvements in asthma control were lower for Symbicort as needed compared to a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) given with a short-acting beta-2-agonist to be used as needed (SYGMA 1: 0.15, 95% CI 0.10 to 0.20; SYGMA 2: 0.11, 95% CI 0.07 to 0.15, both p-value < 0.001). For both comparisons, mean differences in treatments’ effect upon ACQ5 are not clinically meaningful (as assessed by a difference of greater than or equal to 0.5). These results were observed in a clinical study setting with considerably higher adherence to budesonide maintenance dosing than expected in real life.
twice daily) given with a short-acting beta-2-agonist to be used as needed. For both comparisons, mean differences in treatments' effect were small (approximately 30 to 55 mL, equating to approximately 2% of the baseline mean).

Overall, the results of the SYGMA studies show that SYMBICORT anti-inflammatory reliever therapy is a more effective treatment than a short-acting beta-2-agonist as needed in patients with mild asthma. In addition, these studies suggest that the as-needed use of SYMBICORT may be considered an alternative treatment option for patients with mild asthma who are eligible for inhaled corticosteroid treatment.

In a separate clinical programme, a total of 12076 asthma patients were included in 5 double-blind clinical studies (4447 were randomised to SYMBICORT anti-inflammatory reliever plus maintenance therapy – therapy B) for 6 or 12 months. Patients were required to be symptomatic despite daily use of inhaled glucocorticosteroids. SYMBICORT anti-inflammatory reliever plus maintenance therapy provided statistically significant and clinically meaningful reductions in severe exacerbations by prolonging time to first event and reducing the event rate (Table 2), as compared with all comparator treatments, including SYMBICORT at a higher maintenance dose (in Study 735). Symptom control, lung function and reliever use were similar compared with a higher maintenance dose of SYMBICORT, and all three parameters were improved compared with SYMBICORT at the same maintenance dose or budesonide at a 2 to 4 times higher maintenance dose.

### Table 2

**Overview of severe exacerbations in clinical studies**

<table>
<thead>
<tr>
<th>Study No., Age group</th>
<th>Treatment groups a</th>
<th>N</th>
<th>Severe exacerbations b</th>
<th>Exacerbations/patient-year c</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYGMA 1 (Therapy A*)</td>
<td>SYMBICORT 160/4.5 as needed&lt;br&gt;Terbutaline 0.4 mg as needed&lt;br&gt;Budesonide 200 µg bd + terbutaline 0.4 mg as needed</td>
<td>1277 1277 1282</td>
<td>77 188 89</td>
<td>0.07 0.20 0.09</td>
</tr>
<tr>
<td>SYGMA 2 (Therapy A*)</td>
<td>SYMBICORT 160/4.5 as needed&lt;br&gt;Budesonide 200 µg bd + terbutaline 0.4 mg as needed</td>
<td>2084 2083</td>
<td>217 221</td>
<td>0.11 0.12</td>
</tr>
<tr>
<td>6-month double-blind studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 735, (Therapy B**)</td>
<td>SYMBICORT 160/4.5 µg bd + as needed&lt;br&gt;SYMBICORT 320/9 µg bd + terbutaline 0.4 mg as needed&lt;br&gt;Salmeterol/fluticasone 2x25/125 µg bd + terbutaline 0.4 mg as needed</td>
<td>1103 1099 1119</td>
<td>125 173 208</td>
<td>0.23 0.32 0.38</td>
</tr>
<tr>
<td>Study 667, (Therapy B**)</td>
<td>SYMBICORT 2 x 80/4.5 µg od + as needed&lt;br&gt;Budesonide 2 x 160 µg od + terbutaline 0.4 mg as needed</td>
<td>354 342</td>
<td>14 57</td>
<td>0.08 0.35</td>
</tr>
<tr>
<td>12-month double-blind studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 734, (Therapy B**)</td>
<td>SYMBICORT 160/4.5 µg bd + as needed&lt;br&gt;SYMBICORT 160/4.5 µg bd + formoterol 4.5 µg as needed</td>
<td>1107 1137</td>
<td>194 296</td>
<td>0.19 0.29</td>
</tr>
<tr>
<td>Study No., Age group</td>
<td>Treatment groups a</td>
<td>N</td>
<td>Severe exacerbations b</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------</td>
<td>-----</td>
<td>-----------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Number of events</td>
<td>Exacerbations/patient-year c</td>
</tr>
<tr>
<td>≥ 12 years</td>
<td>SYMBICORT 160/4.5 µg bd + terbutaline 0.4 mg as needed</td>
<td>1138</td>
<td>377</td>
<td>0.37</td>
</tr>
<tr>
<td>Study 673, Therapy B** 4-80 years a</td>
<td>SYMBICORT 80/4.5 µg bd + as needed</td>
<td>922</td>
<td>160</td>
<td>0.19***</td>
</tr>
<tr>
<td></td>
<td>SYMBICORT 80/4.5 µg bd + terbutaline 0.4 mg as needed</td>
<td>906</td>
<td>330</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td>Budesonide 320 µg bd + terbutaline 0.4 mg as needed</td>
<td>925</td>
<td>294</td>
<td>0.35</td>
</tr>
<tr>
<td>4-11 years</td>
<td>SYMBICORT 80/4.5 µg od + as needed</td>
<td>118</td>
<td>11</td>
<td>0.10***</td>
</tr>
<tr>
<td></td>
<td>SYMBICORT 80/4.5 µg od + terbutaline 0.4 mg as needed</td>
<td>117</td>
<td>52</td>
<td>0.46</td>
</tr>
<tr>
<td></td>
<td>Budesonide 320 µg od + terbutaline 0.4 mg as needed</td>
<td>106</td>
<td>32</td>
<td>0.33</td>
</tr>
<tr>
<td>Study 668, 12-80 years</td>
<td>SYMBICORT 2 x 160/4.5 µg od + as needed</td>
<td>947</td>
<td>197</td>
<td>0.23***</td>
</tr>
<tr>
<td></td>
<td>Budesonide 2 x 160 µg bd + terbutaline 0.4 mg as needed</td>
<td>943</td>
<td>349</td>
<td>0.42</td>
</tr>
</tbody>
</table>

* SYMBICORT anti-inflammatory reliever therapy.
** SYMBICORT anti-inflammatory reliever plus maintenance therapy.
*** Reduction in exacerbation rate is statistically significant (p-value < 0.01) (for both comparisons where applicable).

- a All doses expressed as metered dose. Pulmicort 200 µg and 400 µg (metered doses) correspond to budesonide 160 µg and 320 µg (delivered doses), respectively.
- b Defined as hospitalisation/emergency room treatment or treatment with oral steroids due to asthma (and for children, also an increase in inhaled steroid dose or additional asthma treatment).
- c Data normalised to 12 months for studies 735, 667, 734 and 673.
- d Reduction in exacerbation rate is statistically significant (p-value <0.001) for the comparison of Symbicort as needed vs Terbutaline as needed.
- e Reduction in exacerbation rate is not statistically significantly different (p-value 0.279) when comparing Symbicort as needed vs Budesonide 200 µg bd + terbutaline 0.4 mg as needed in SYGMA 1.
- f Symbicort as needed was non-inferior to Budesonide 200 µg bd + terbutaline 0.4 mg as needed in reducing the severe exacerbation rate in SYGMA 2. The upper limit (1.16) of the 95% CI for the rate ratio (RR) was below the pre-specified non-inferiority limit (1.20). Includes children ages 4 to 11 that received half the maintenance dose, who are also presented separately.

Analysis of time to first severe exacerbation in the SYGMA 1 study showed that the likelihood of experiencing a severe exacerbation was statistically significantly higher for the as-needed use of a short-acting beta-2-agonist compared to the as-needed use of SYMBICORT (SYMBICORT anti-inflammatory reliever therapy - therapy A) over the 1 year treatment period (see Figure 1a), with a risk reduction of 56% ([IHR] 0.44, 95% CI: 0.33-0.58, p-value < 0.001). There were no differences in the probability of experiencing a severe exacerbation between SYMBICORT anti-inflammatory reliever therapy (therapy A) and a therapy including a maintenance dose of budesonide (1 inhalation of 200 micrograms/inhalation twice daily) and a short-acting beta-2-agonist used as needed (see Figure 1a and 1b).
Figure 1a  Time to first severe asthma exacerbation in SYGMA 1 study

Figure 1b  Time to first severe asthma exacerbation in SYGMA 2 study

In Study 735, SYMBICORT anti-inflammatory reliever plus maintenance therapy (therapy B) significantly prolonged the time to the first severe exacerbation (see Figure 2a) compared to the other treatment groups. The rate of severe exacerbations was reduced by 28% compared to twice the maintenance dose of SYMBICORT with terbutaline as reliever. Lung function, symptom control, and reliever use were similar in all treatment groups.

Figure 2a  Time to first severe asthma exacerbation in study 735

Figure 2b  Time to first severe asthma exacerbation in study 734

In Study 734, SYMBICORT anti-inflammatory reliever plus maintenance therapy (therapy B) prolonged the time to the first severe exacerbation compared to SYMBICORT at the same maintenance dose with either formoterol or terbutaline as reliever (see Figure 2b). The rate of severe exacerbations was reduced by 33% and 48%, respectively. Symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments.

In Studies 673, 668 and 667, SYMBICORT anti-inflammatory reliever plus maintenance therapy (therapy B) prolonged the time to the first exacerbation compared to SYMBICORT at the same maintenance dose with terbutaline as reliever and compared to a 2- to 4-fold higher maintenance dose of budesonide with terbutaline as reliever. Across the 3 studies, the rate
of exacerbations was reduced by 45-76%. Symptoms and reliever use were reduced and lung function improved compared with all other treatments. For children (118 randomised to SYMBICORT anti-inflammatory reliever plus maintenance therapy in study 673), the exacerbation rate was reduced by 70-79%.

In the 5 long-term studies, patients (adults and adolescents) receiving SYMBICORT anti-inflammatory reliever plus maintenance therapy (therapy B) were allowed 12 inhalations per day (maintenance and as needed) without being reassessed. On average, no reliever inhalation was used on 57% of treatment days and 0-2 reliever inhalations on 87% of treatment days. There was no sign of development of tolerance over time.

In two separate studies with patients seeking medical attention due to acute asthma symptoms, SYMBICORT provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.

Clinical Efficacy in asthma for SYMBICORT maintenance therapy (therapy C)
Clinical studies with SYMBICORT TURBUHALER have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. The effect on lung function of SYMBICORT TURBUHALER, given as maintenance dose only, was equal to that of budesonide and formoterol administered in separate inhalers in adults and exceeded that of budesonide alone in adults and children. All treatment arms used a short-acting beta-2-agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.

Clinical Efficacy in Chronic Obstructive Pulmonary Disease (COPD)
In two 12-month studies in patients with COPD, SYMBICORT TURBUHALER was superior to placebo, formoterol and budesonide regarding lung function, and showed a significant reduction in the exacerbation rate compared to formoterol and placebo. Thus, the contribution of both budesonide and formoterol to the effect of SYMBICORT TURBUHALER was demonstrated. SYMBICORT TURBUHALER was also superior to placebo regarding symptoms and quality of life. The treatment was well tolerated.

5.2 PHARMACOKINETIC PROPERTIES

Absorption
SYMBICORT TURBUHALER and the corresponding monoproducts (Pulmicort Turbuhaler and Oxis Turbuhaler, respectively) have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively.

There was no evidence of pharmacokinetic interactions between budesonide and formoterol.

Pharmacokinetic parameters, for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as SYMBICORT TURBUHALER.

Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is reached within 30 minutes after inhalation.

In studies, mean lung deposition of budesonide after inhalation via Pulmicort Turbuhaler ranged from 32 to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose.
Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation. In studies, the mean lung deposition of efomoterol after inhalation via Oxis Turbuhaler ranged from 28-49% of the delivered dose. The systemic availability is about 61% of the delivered dose.

**Distribution and Biotransformation**

Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6ß-hydroxy-budesonide and 16α-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.

**Elimination**

The major part of a dose of formoterol is eliminated by metabolism in the liver followed by renal excretion. After inhalation of formoterol via Turbuhaler, 8-13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.

Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are excreted in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after intravenous dosing averages 4 hours.

Budesonide has a systemic clearance of approximately 0.5 L/min in 4-6 year old asthmatic children. Per kg body weight children have a clearance which is approximately 50% greater than in adults. The terminal half-life of budesonide after inhalation is approximately 2.3 hours in asthmatic children. The pharmacokinetics of formoterol in children has not been studied.

The pharmacokinetics of budesonide or formoterol in elderly and patients with renal failure is unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.

**5.3 PRECLINICAL SAFETY DATA**

The toxicity observed in animal studies with budesonide and formoterol was similar whether budesonide or formoterol were given in combination or separately. The effects were associated with pharmacological actions and dose dependent.

In animal reproduction studies, glucocorticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses (see section 4.6). Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant to man.
6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS
Lactose monohydrate (which may contain milk protein residue).

6.2 INCOMPATIBILITIES
Not applicable

6.3 SHELF-LIFE
24 months.

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 30°C. Store with cover tightened.

6.5 NATURE AND CONTENTS OF CONTAINER
SYMBICORT TURBUHALER is a multidose inspiratory flow driven, dry powder inhaler. The inhaler is made of plastic parts.

Symbicort 100/6 and 200/6 Turbuhaler: Each inhaler contains 60 doses or 120 doses

Symbicort 400/12 Turbuhaler: Each inhaler contains 60 doses.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
Return unused and expired medicines to your local pharmacy for disposal.

7. MEDICINE SCHEDULE
Prescription Medicine

8. SPONSOR
AstraZeneca Limited
PO Box 87453
Meadowbank
Auckland 1742.
Telephone: (09) 306 5650

9. DATE OF FIRST APPROVAL
100/6 and 200/6: 2 August 2001
400/12: 18 July 2002

10. DATE OF REVISION OF THE TEXT
20 July 2020

CDS 260620
Symbicort and Turbuhaler are registered trademarks of the AstraZeneca group of companies.

© AstraZeneca 2020.

### SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>Pneumonia in COPD patients subsection amended in line with recent data.</td>
</tr>
<tr>
<td>4.5</td>
<td>Update of the CYP inhibitors information</td>
</tr>
<tr>
<td>4.6</td>
<td>Update to figures based on latest data</td>
</tr>
<tr>
<td>4.8</td>
<td>New ADR (pneumonia) included in Table 1</td>
</tr>
<tr>
<td>8</td>
<td>PO Box address amended.</td>
</tr>
<tr>
<td>General</td>
<td>Minor editorial changes.</td>
</tr>
</tbody>
</table>